Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present updated data from the ongoing Phase 2 ANCHOR (OP-104) triple combination study at the ASH Annual Meeting 2019. In the data presented, melflufen and dexamethasone demonstrated positive efficacy in combination with daratumumab or bortezomib in patients with relapsed/refractory multiple myeloma (RRMM). Preclinical data supporting clinical development of melflufen in AL amyloidosis will also be presented for the first time.
Overall Conclusions – ANCHOR Poster Presentation
· Patients in the ANCHOR study had a median of two prior lines of therapy. All patients were refractory to at least one agent.
· For melflufen and dexamethasone in combination with daratumumab (n=33) the overall response rate (ORR) was 76% with a median progression-free survival (PFS) of 14.3 months.
· 70% of the patients were still progression-free at the time of the data cut.
· For melflufen and dexamethasone in combination with bortezomib (n=6) the ORR was 67%.
· Responses improved with continued therapy for both combinations.
· Both combinations were well tolerated and the grade 3 and 4 Adverse Events (AE) were primarily hematologic.
· For melflufen and dexamethasone in combination with daratumumab (n=33) the overall response rate (ORR) was 76% with a median progression-free survival (PFS) of 14.3 months.
· 70% of the patients were still progression-free at the time of the data cut.
· For melflufen and dexamethasone in combination with bortezomib (n=6) the ORR was 67%.
· Responses improved with continued therapy for both combinations.
· Both combinations were well tolerated and the grade 3 and 4 Adverse Events (AE) were primarily hematologic.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.